SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Palantir Technologies, Inc. engages in the business of building and deploying software platforms that serve as the central operating systems for its customers. It operates through the Commercial and Government segments. The Commercial segment focuses on customers working in non-government industries. The Government segment is involved in providing services to customers that are the United States government and non-United States government agencies. Its platforms are widely used in areas such as defense, intelligence, healthcare, energy, and financial services, supporting data integration, large-scale analytics, and operational decision-making. The company was founded by Alexander Ceadmon Karp, Peter Andreas Thiel, Stephen Cohen, Joseph Lonsdale, and Nathan Dale Gettings in 2003 and is headquartered in Aventura, FL.

Palantir Technologies Inc - Ordinary Shares - Class A

Palantir Technologies Inc

Palantir Technologies is capturing significant attention following a strong earnings report that featured record revenue growth and raised forward guidance, fueling intense debate between long-term bulls and skeptical critics. While the community is actively discussing the stock's high valuation and the role of its AI platform, many traders remain focused on the potential for institutional volatility and the ongoing clash between strong fundamentals and market manipulation theories.

Elong Power Holding Ltd. engages in the research and development, manufacturing, sales and service of high-power lithium-ion batteries for electric vehicles and construction machinery, as well as large-capacity, long-cycle lithium-ion batteries for energy storage systems. The company was founded on August 18, 2023 and is headquartered in Ganzhou, China.

Elong Power Holding Ltd. - Ordinary Shares - Class A

Elong Power Holding Limited

Elong Power Holding Limited is trending due to significant trading volume and volatile price action that has attracted momentum traders looking for potential short-squeeze setups. The community is actively discussing the stock's low-float structure, recent reverse splits, and the recurring pattern of sharp price swings often seen in similar China-based microcap plays.

GameStop Corp. engages in offering games and entertainment products through its ecommerce properties and stores. The firm’s stores and ecommerce sites operate primarily under the names GameStop, EB Games, and Micromania. It operates through the following geographical segments: United States, Canada, Australia, and Europe. The company was founded by Daniel A. DeMatteo in 1996 and is headquartered in Grapevine, TX.

Gamestop Corporation - Ordinary Shares - Class A

GameStop Corp

GameStop shares are experiencing high volatility as investors react to an unsolicited acquisition bid for eBay, fueling intense debate regarding the feasibility of such a large-scale transaction and the potential for significant share dilution. While some community members view the bold move as a calculated strategic play by leadership, others are expressing skepticism and concern over the CEO's communication, leading to active speculation about his true intentions and the future impact on shareholder value.

Invesco QQQ Trust Series 1 - Invesco QQQ Trust Series 1

Investors are actively debating the sustainability of current stock valuations as market participants weigh resilient corporate earnings and AI-driven productivity gains against escalating geopolitical tensions in the Middle East and rising energy costs. The community remains sharply divided, with bulls pointing to the market's refusal to sell off on negative headlines as evidence of institutional support, while bears express concern over the lack of traditional technical pullbacks amidst record-high RSI levels and perceived disconnects from fundamental macro data.

SKK Holdings Ltd. operates as a holding company, which engages in the provision of civil engineering services in subsurface utility works, including power and telecommunication cable laying, water pipeline and sewer rehabilitation works. The company was founded by Chun Seong Ng and Koon Kiat Sze on October 16, 2013 and is headquartered in Singapore.

SKK Holdings Ltd. - Ordinary Shares - Class A

SKK Holdings Ltd

SKK is experiencing massive volatility driven by a major drone asset acquisition agreement, with the community polarized between traders chasing the extreme low-float momentum and skeptics warning of dilution risks. Participants are actively debating whether the stock's parabolic move is a sustainable short squeeze or a classic pump-and-dump cycle.

Mask Network is the core product of Dimension, which is positioned to become the bridge that connects internet users from Web 2.0 to Web 3.0. The foundational technology of Mask Network is a peer-to-peer encrypted messaging application, with new functions continuously being created around this foundation. We at Mask Network are strong believers in the ownership economy. People should own what they produce, people should own their data, their attention and the virtual space they choose to contribute to.  Mask Network integrates decentralized social messaging, borderless payment network, and decentralized file storage and sharing to provide a safe and convenient portal for users to jump right into the continent of decentralized finance and then the new world of Web 3.0.

Mask Network

Mask Network is gaining significant momentum as traders react to a new institutional convertible note agreement, fueling speculation about its pivot toward AI infrastructure. Community discourse is heavily focused on the stock's low float and potential for a sharp, scanner-driven squeeze.

SoundHound AI, Inc. engages in the development, owning, and commercialization of voice, sound, and natural language artificial intelligence technologies and related activities. The company was founded on September 2, 2005 and is headquartered in Santa Clara, CA.

SoundHound AI Inc - Ordinary Shares - Class A

SoundHound AI Inc

SoundHound AI is experiencing significant market interest driven by an intense short squeeze setup, with community members highlighting high borrow fees and a scarcity of shares available to short. Investors are closely monitoring the stock ahead of upcoming earnings, with active discussions focused on the potential for a gamma squeeze if the share price sustains key psychological breakout levels.

Duolingo, Inc. is a language-learning website and mobile application, which engages in the development of a free language learning website and crowd sourced text translation platform. It offers Duolingo for Schools, a free, web-based tool that aims to make it easier for teachers to use the Duolingo platform in a structured learning environment, and English Test, an online, on-demand assessment of English proficiency. The company was founded by Luis von Ahn and Severin Hacker in 2011 and is headquartered in Pittsburgh, PA.

Duolingo Inc - Ordinary Shares - Class A

Duolingo Inc

Duolingo is seeing intense investor debate as a significant earnings sell-off drives concerns over slowing growth and potential AI disruption, despite strong engagement metrics and profitability. Community sentiment remains sharply divided between those viewing the pullback as a generational buying opportunity and skeptics who fear the platform is becoming obsolete in the era of advanced AI tutors.

iShares Trust - iShares 20+ Year Treasury Bond ETF

iShares 20+ Year Treasury Bond ETF

The iShares 20+ Year Treasury Bond ETF is trending as investors grapple with bond market volatility driven by rising geopolitical tensions in the Middle East and concerns over persistent inflation. Community discussions are heavily divided, featuring debates between those viewing the current price levels as a bargain opportunity and traders betting on further downside due to uncertainty surrounding interest rate policy and economic growth.

Willow Lane Acquisition Corp. is a blank check company, which engages for the purpose of effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization, or similar business combination with one or more businesses. The company was founded on July 3, 2024 and is headquartered in New York, NY.

Willow Lane Acquisition Corp. - Ordinary Shares - Class A

Willow Lane Acquisition Corp. is trending as investors monitor the imminent merger with Boost Run, an AI infrastructure provider, following a major purchase agreement with Dell Technologies. The community is actively discussing the stock's potential as a low-valuation play in the AI compute sector, with significant focus on the upcoming ticker change to BRUN and the strategic implications of the firm's NVIDIA partnership.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Small-Cap ETF (SFLO) Hits New 52-Week High

SFLO hits a 52-week high, up about 50% from lows; strong cash flow focus and small-cap resilience may support further near-term upside.

<ul class="summary-bullets"><li>Analysts at JPMorgan downgraded StubHub to ‘neutral’ from ‘overweight’ while reducing the price target to $10 from $12.</li><li>The firm cited StubHub’s guidance reset for 2026 as the reason for the downgrade, while highlighting that the company will need to build credibility with investors.</li><li>Wedbush stated that it has “limited conviction and visibility” regarding StubHub’s direct issuance business.</li></ul>StubHub Holdings Inc.’s (STUB) lackluster fourth-quarter (Q4) results drew a spate of downgrades from Wall Street, with analysts pointing to a series of concerns about the company’s future outlook and the regulatory environment.<a href="https://stocktwits.com/symbol/STUB">StubHub shares</a> tumbled more than 14% in Thursday’s pre-market trade. Retail sentiment on Stocktwits around the company trended in the ‘extremely bullish’ territory at the time of writing.<h2 class="st-heading-2">Why Is Wall Street Worried?</h2>Analysts at JPMorgan downgraded StubHub to ‘neutral’ from ‘overweight’ while reducing the price target to $10 from $12. The firm cited StubHub’s guidance reset for 2026 as the reason for the downgrade, while highlighting that the company will need to build credibility with investors.JPMorgan stated that StubHub’s 2026 earnings before interest, taxes, depreciation, and amortization (EBITDA) guidance is now 60% lower than what the company projected in October 2025. The firm said that while the new outlook “may finally be achievable,” it will have to work through the lock-up expiration beginning March 9, 2026, and also overcome ongoing regulatory concerns around the company.Analysts at Wedbush also downgraded StubHub to ‘neutral’ from ‘outperform’ and lowered the price target by 80% to $10 from $18. The firm stated that it has “limited conviction and visibility” in StubHub’s direct issuance business, noting that the ticket resale broker’s management’s “lofty” expectations are not materializing.Wedbush also stated that regulatory risks will remain an overhang on the stock, while adding that the company is vulnerable to AI-enabled disintermediation in the coming years, given that companies operating in the space face the risk from commoditization.<h2 class="st-heading-2">StubHub’s Q4 At A Glance</h2>StubHub reported a loss of $1.56 per share in Q4, compared to earnings per share (EPS) of $0.13 during the same quarter a year ago. Wall Street expected the company to report a loss of $0.02 per share during the quarter, according to Fiscal.ai data.The company’s revenue in Q4 was $449 million, down from $533 million in the year-ago period. Wall Street consensus projected StubHub to report revenue of $485 million during the period.StubHub’s founder and CEO, Eric Baker, remained optimistic about the company’s prospects, stating that 2025 reinforced that the ticket resale broker’s mission is as relevant as ever. “Our full-year performance validates our long-term strategy and the substantial value we're creating for fans, partners, and shareholders alike,” he said.<h2 class="st-heading-2">How Did Stocktwits Users React To STUB?</h2>One user on Stocktwits pointed to macroeconomic challenges in the U.S., adding that the amount of money people have to spend on “luxuries” is declining.<stembedurl>https://stocktwits.com/insanitywolftrading/message/646656600</stembedurl>However, a bullish user said that StubHub is a “solid company with actually great earnings.”<stembedurl>https://stocktwits.com/llevi/message/646632021</stembedurl><a href="https://stocktwits.com/symbol/STUB">STUB stock</a> is down 25% year-to-date and 64% over the past 12 months.Also See:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/pdyn-stock-soars-q4-beat-palladyne-ai-ceo-touts-deeper-defense-engagement/cZdQqg1RI3P">Palladyne AI CEO Touts Expanded Backlog, Deeper Defense Engagement After Q4 Beat Sends PDYN Stock Soaring</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

The StubHub logo and webpage are displayed on a cell phone and computer monitor. (Photo Illustration by Mario Tama/Getty Images)

StubHub's Q4 Miss Draws Multiple Downgrades From Wall Street – Analysts Warn Of ‘Credibility’ Gap

StubHub reported a loss of $1.56 per share in Q4, compared to earnings per share of $0.13 during the same quarter a year ago, while Wall Street expected a loss of $0.02 per share.

Equity

<ul class="summary-bullets"><li>The outlook includes $150 million to $170 million from DefenCath, with results weighted toward the first half of the year.</li><li>The company expects adjusted EBITDA for 2026 to be between $100 million and $125 million.</li><li>CorMedix is commercializing a portfolio of anti-infective products.</li></ul>Shares of CorMedix Therapeutics (CRMD) plunged 28% on Thursday after the company issued a cautious full-year 2026 outlook, signalling revenue could come in below 2025 levels.<a href="https://stocktwits.com/symbol/CRMD">CRMD</a> was among the top trending stocks at the time of writing.CorMedix posted net revenue of around $127 million in the fourth quarter (Q4) of 2025 and $310 million for the full year, with pro forma full-year revenue of about $400 million. Adjusted earnings before interest, tax, depreciation and amortization (EBITDA) for Q4 is expected to range between $77 million and $81 million.<h2 class="st-heading-2">Full-Year Expectations</h2>For 2026, CorMedix expects revenue between $300 million and $320 million, including $150 million to $170 million from DefenCath, with performance weighted toward the first half of the year. DefenCath is an FDA-approved catheter lock solution used to reduce bloodstream infections in certain adult dialysis patients with central venous catheters.Adjusted EBITDA for 2026 is projected at $100 million to $125 million, supported by $35 million in annualized cost synergies from the Melinta acquisition. Last August, CorMedix acquired Melinta Therapeutics in a $300 million deal, which also includes up to $25 million in regulatory milestone payments and royalties.<h2 class="st-heading-2">Key Updates</h2>Commercial momentum continues to be driven by DefenCath, which is seeing strong utilization and patient growth among outpatient dialysis customers. CorMedix noted that reimbursement for DefenCath will decline in the second half of 2026 as the Transitional Drug Add-on Payment Adjustment&nbsp;(TDAPA) transitions to a post-TDAPA add-on adjustment, pressuring pricing later in the year.However, the company expects reimbursement to improve in 2027, potentially supporting higher pricing compared to late 2026.On the clinical front, Phase 3 data from the ReSPECT study of REZZAYO antifungal medication is expected in Q2 2026, while enrollment continues in a Phase 3 study of DefenCath in total parenteral nutrition (TPN) patients. CorMedix is also commercializing a portfolio of anti-infective products.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>Despite the sharp intraday decline, retail sentiment on Stocktwits flipped to ‘bullish’ from ‘bearish’ a day earlier, amid ‘high’ message volumes. CRMD was among the top trending tickers on the platform.<img src="https://news.stocktwits-cdn.com/CRMD_jpg_84acb69cec.webp" alt="CRMD.jpg">One user questioned the company’s financial outlook.<stembedurl>https://stocktwits.com/Spoonorama/message/641198820</stembedurl>Another user sounded skeptical about the company’s second-half performance.<stembedurl>https://stocktwits.com/Brunoez/message/641203929</stembedurl>Over the past year, the stock has declined about 20%.Read also: <a href="https://stocktwits.com/news-articles/markets/equity/why-did-mltx-stock-jump-45-in-pre-market-today/cmUbJFWR4Pt">Why Did MLTX Stock Jump 45% In Pre-Market Today?</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the CorMedix logo is seen displayed on the screen of a tablet. (Photo Illustration by Sheldon Cooper/SOPA Images/LightRocket via Getty Images)

Why Did CRMD Stock Crash 28% Today?

CorMedix announced that for 2026, it expects revenue between $300 million and $320 million, compared to $310 million it reported in the full year 2025, according to preliminary data.

<ul class="summary-bullets"><li>The company now expects full-year revenue to be $845 million to $865 million, up from the previous range of $820 million to $860 million.</li><li>It said that the Wakix franchise delivered net revenue of approximately $239 million in the third quarter.&nbsp;</li></ul>Shares of Harmony Biosciences Holdings (HRMY) jumped 6% in the premarket session on Thursday after the company raised its full-year revenue guidance on strong Wakix sales.The firm now <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.businesswire.com/news/home/20251023496242/en/Harmony-Biosciences-Preannounces-Strong-Q3-2025-WAKIX-Performance-Raises-2025-Revenue-Guidance">expects</a> full-year revenue to be $845 million to $865 million, up from the previous range of $820 million to $860 million.<h2 class="st-heading-2">Excessive Sleepiness Medication Drives Revenue</h2>The company said that its Wakix franchise delivered net revenue of approximately $239 million in the third quarter (Q3), representing 29% year-over-year revenue growth. Wakix is approved by the U.S. Food and Drug Administration for the treatment of excessive daytime sleepiness (EDS) or cataplexy in adult patients with narcolepsy and for the treatment of EDS in pediatric patients six years of age and older with narcolepsy.Narcolepsy is a chronic neurological disorder affecting the brain's ability to regulate sleep-wake cycles, causing excessive daytime sleepiness and uncontrollable sleep attacks. Other symptoms include sudden loss of muscle control called cataplexy. The company said the increase in Wakix revenue was driven by higher average patient volume.The company is expected to report full Q3 earnings on November 4.<h2 class="st-heading-2">What Are Stocktwits Users Saying?</h2>On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/HRMY">HRMY stock</a> jumped from ‘bearish’ to ‘neutral’ over the past 24 hours, while message volume remained at ‘low’ levels.Last month, the company <a href="https://stocktwits.com/news-articles/markets/equity/harmony-biosciences-stock-slumps-after-rare-genetic-disorder-drug-fails-late-stage-study/chD1BhBR3Ed">announced</a> that its late-stage study of ZYN002 in Fragile X syndrome did not meet the primary endpoint of improvement in social avoidance due to a higher-than-expected placebo response rate. Fragile X syndrome (FXS) is a rare genetic disorder that negatively affects synaptic function, plasticity, and neuronal connections. It results in a spectrum of intellectual disabilities and behavioral symptoms, such as social avoidance and irritability.CEO Jeffrey M. Dayno then highlighted the company’s strong portfolio, noting that it is on track to initiate late-stage trials of Wakix in narcolepsy and idiopathic hypersomnia in the fourth quarter of this year.HRMY shares are down 24% this year and by about 23% over the past 12 months.&nbsp;Read also: <a href="https://stocktwits.com/news-articles/markets/equity/tesla-recalls-nearly-64000-cybertrucks-over-concerns-with-front-parking-lights/cLG4hXGR3AH">Tesla Recalls Nearly 64,000 Cybertrucks Over Concerns With The Front Parking Lights</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Global stock market chart and trading board - stock photo

Harmony Biosciences Raises Full-Year Revenue Guidance Ahead Of Earnings: Why Are Wakix Franchise Numbers Crucial?

The company now expects full-year revenue to be $845 million to $865 million, up from the previous range of $820 million to $860 million.

Is Now the Time to Buy Small-Cap Stocks?

We discuss the outlook for small-cap stocks and highlight four ETFs.

The Zacks Analyst Blog Highlights MCOW, SCOW, SFLO and CALF

Pacer???s new MCOW and SCOW ETFs spotlight quality small- and mid-cap firms with strong free cash flow, joining rivals SFLO and CALF.

Looking for Quality ETFs in Smaller Caps? Tap 2 New FCF Aristocrats 

MCOW and SCOW debut with quality-focused strategies, targeting mid- and small-cap stocks with strong free cash flow records.



SFLO
Victory Portfolios II - VictoryShares Small Cap Free Cash Flow ETF

Feed

News

Sentiment

Fundamentals

Info

Compact View

Poll

Latest SFLO News

SFLOVictory Portfolios II - VictoryShares Small Cap Free Cash Flow ETF